Decisions on the reimbursement of the cost of medicines were neither political nor ministerial, Taoiseach Enda Kenny has said.

He said they were made on objective, scientific and economic grounds by the Health Service Executive on the advice of the National Centre for Pharmacoeconomics (NCPE).

Mr Kenny was replying to Fianna Fáil leader Micheál Martin, who said a ground-breaking drug, Orkambi, had arrived on the market to treat cystic fibrosis (CF).

"The response of the authorities in the health service plan, and that of the Government, is that no funding will be made available in 2016 to provide the drug for patients," Mr Martin said. "The HSE is clear that if the Government wants to fund it, it will have to provide it with additional money."

Mr Kenny said last month the manufacturer of the drug had submitted a rapid review application to the NCPE as the first step in a pricing and reimbursement application.

The HSE estimated the cost could be about €90 million annually, he said.

“Given the significant budgetary impact, the NCPE is likely to require a full technology assessment of the drug to be carried out before making any recommendation to the HSE on reimbursement, in keeping with the normal procedure.”

Mr Kenny said the Department of Health and the HSE had made significant improvements to the facilities for CF sufferers around the country, particularly isolation units.

“This matter is part of the application process which has a journey to travel,” he said.

Mr Martin said the bottom line was there was no extra provision for the high-tech drug scheme next year, despite the escalating cost of treatment.